Jeff Liter

President & CEO
Steamboat Springs, Colorado, United States

Professional Overview

Jeff Liter is an accomplished biopharmaceutical executive with extensive experience in leading innovative therapeutic development organizations. As the President and CEO of OX2 Therapeutics and Luminary Therapeutics, Inc., he leverages his deep industry expertise to drive the advancement of groundbreaking treatments for complex medical conditions.

Experience Summary

Current Roles

President & CEO, OX2 Therapeutics (2016-09-01 to Present)

• Responsible for the overall strategic direction and operational management of OX2 Therapeutics, a leading biotechnology company focused on developing novel therapeutics for rare and orphan diseases.

• Spearheaded the successful clinical advancement of OX2's lead product candidate, demonstrating significant improvements in patient outcomes.

• Secured multiple strategic partnerships and collaborations, accelerating the company's research and development efforts.

President & CEO, Luminary Therapeutics, Inc. (2019-07-01 to Present)

• Oversees the strategic vision and day-to-day operations of Luminary Therapeutics, a biopharmaceutical firm dedicated to innovative drug discovery and development.

• Guided the company's portfolio expansion, with the introduction of several promising therapeutic candidates targeting unmet medical needs.

• Fostered a culture of innovation and collaboration, empowering the Luminary Therapeutics team to achieve significant milestones.

Career Progression

President & CEO, B-MoGen Biotechnologies Inc. (2015-09-01 to 2021-08-01)

• Served as the President and CEO of B-MoGen Biotechnologies, a pioneering biotechnology company focused on developing transformative cell and gene therapies.

• Spearheaded the company's successful research and development initiatives, culminating in the advancement of multiple product candidates to clinical trials.

• Secured significant funding and investment, enabling B-MoGen to expand its operations and accelerate its innovation pipeline.

Sr. Principal, West Monroe Partners (2014-11-01 to 2016-06-01)

• Provided strategic consulting services to clients in the healthcare and life sciences sectors, advising on business transformation, operational efficiency, and regulatory compliance.

• Leveraged deep industry expertise to help clients navigate complex challenges and capitalize on emerging opportunities.

Chief Operating Officer, Progenitor Cell Therapy a Division of NeoStem (2012-09-01 to 2014-11-01)

• Served as the Chief Operating Officer for Progenitor Cell Therapy, a division of NeoStem, a leading cell therapy company.

• Optimized operational processes, enhanced production capabilities, and drove the successful launch of multiple cell-based therapeutic products.

Academic Background

Jeff Liter holds a Master of Business Administration (MBA) from the University of Chicago Booth School of Business and a Bachelor of Science (BS) in Biomedical Engineering from the University of Michigan.

Areas of Expertise

• Biopharmaceutical drug development

• Cell and gene therapy innovation

• Strategic leadership and executive management

• Regulatory compliance and clinical trial management

• Biotech industry and market dynamics

• Fundraising and capital investment

Professional Impact

• Spearheaded the successful clinical advancement of multiple therapeutic candidates, demonstrating significant improvements in patient outcomes.

• Secured strategic partnerships and collaborations, accelerating research and development efforts and expanding the reach of his companies' innovations.

• Fostered a culture of innovation and collaboration, empowering teams to achieve significant milestones and drive the advancement of transformative therapies.

• Secured substantial funding and investment, enabling the expansion of operations and the acceleration of innovation pipelines.

Conclusion

With his extensive experience in the biopharmaceutical industry and a proven track record of leading innovative therapeutic development organizations, Jeff Liter is well-positioned to continue driving the advancement of groundbreaking treatments and creating lasting impact in the field of healthcare.